Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alternating neoadjuvant chemotherapy in pancreatic cancer
NCT03703063Phase 1Unknown
- Sponsor
- Benaroya Research Institute
- Start
- Sep 2018
- Primary completion
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of irinotecan liposome injection in pancreatic adenocarcinoma (PDAC), sponsored by Benaroya Research Institute. Status: unknown.
02
Drugs
irinotecan liposome injection
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT03703063.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03703063.